Table 4
Cellular IC50 (nM) of imatinib (IM), nilotinib (NI), and dasatinib (DA) and fold increase with respect to the IC50 for wild-type (WT) Bcr-Abl of the F311L, T315I, F317L, M351T, F359V, V379I, L384M, L387M, H396R, H396P, and F486S mutant forms
View large
Cellular IC50 (nM) of imatinib (IM), nilotinib (NI), and dasatinib (DA) and fold increase with respect to the IC50 for wild-type (WT) Bcr-Abl of the F311L, T315I, F317L, M351T, F359V, V379I, L384M, L387M, H396R, H396P, and F486S mutant forms

Data were collated from 10 published studies. As far as the remaining mutations are concerned, IC50 values (and fold changes in IC50), when available, are not included in these tables because they have been assessed in single studies: D276G, 1147nM (2.2), 35.3nM (2), and 2.6nM (1.4) for IM, NI, and DA, respectively;77  T315A, 760nM (2.4) and 125nM (93) for IM and DA, respectively;47  F317V, 500nM (1.6) and 350nM (25) for IM and NI, respectively;75  F317C, 1200nM (3.8) for IM;75  and E355G, 2380nM (4) for IM.6 

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal